Tel: +44 (0) and bicinconnic acid protein assay, and stability was evaluated using SDS-PAGE.
6 leads to hypoglycaemic shock (11) . However, the primary concern is poor stability of 91 insulin after exposure to formulation conditions present during the emulsification and 92 solvent removal-based processes (12) . The primary emulsification phases are of particular 93 concern (13) . Emulsification of the primary aqueous protein solution with an immiscible 94 solvent, such as dichloromethane, facilitates protein aggregation at the aqueous-organic 95 interfacial boundary (14) . The end result is incomplete release (15) or low encapsulation 96 efficiencies (16) .
97
There is a need to improve the sustained release kinetics of insulin and biologically 98 active peptides from biodegradable carriers, whilst preserving activity during fabrication.
99
Formulation studies using potent peptides is often hampered given that available quantities 100 of peptide are often low. Using model drugs, such as insulin, is a common strategy which 101 gathers preliminary data. Formulation of insulin-loaded NP by the double-emulsion 102 technique is commonly done by shearing the system with either sonication or 103 homogenisation (17) . Encapsulating insulin using sonication gives high insulin burst 104 release and low entrapment efficiency as troublesome consequences (18) . Emulsification 105 using homogenising maintains a linear release profile and higher encapsulation efficiency 106 of hydrophilic drugs that cannot be achieved in particles fabricated by sonication (17) , but 7 insulin/polymer loading ratio and concentration of poly(vinyl alcohol) in the internal 114 aqueous phase, on the physicochemical characteristics of insulin-loaded NP, together with 115 in vitro release profiles and stability were investigated. Furthermore, we evaluated in vivo 116 insulin activity using the IP route, as administration is relatively straightforward in the 117 murine model. It is also relevant to the development of continuous intraperitoneal insulin 118 infusion. IP insulin has been shown to provide adequate glycaemic control, which appears 119 superior to that seen following treatment with conventional SC insulin (19) . However, the 120 approach is not without its clinical difficulties and more data is needed to assess long-term 121 safety, which will include evaluation of novel delivery strategies, such as nanoparticulate 122 platforms (19 
Preparation of insulin-loaded NP

138
A modified, double-emulsion, solvent evaporation technique was used in this work, as 139 illustrated schematically in Fig. 1 (20) . Insulin was dissolved in 0. insulin into the continuous water phase (30) .
305
The in vitro release profiles and the initial bursts were directly related to the degree 306 of theoretical insulin loading, as shown in Fig. 3, 4 
340
The effect of internal aqueous phase stabiliser on the insulin release from different
341
NP formulations is shown in Fig. 6 . A significant increase (p<0.05) in the release rate after
342
PVA addition was observed, and the amount of initial release also increased concomitantly.
343
The total amounts of insulin released (p<0.05) when compared to similar data from F9 (Fig. 7) .
365
Release data for F9 and F16 follow a profile that is typical of drug delivery systems that 366 display Higuchi kinetics. Indeed, fitting cumulative percentage drug release data in Fig. 7 367 to the square root of time (data not shown) confirmed this assumption. material was irregular and sheet-like (Fig. 8B) . As F9 has a high PEG content, pore 375 formation during exposure to aqueous media is expected, which may explain poor retention 376 of spherical shape and the enhanced release observed in Fig. 7 (20) . 
Residual PVA
379
PVA is an emulsifier, widely used in the preparation of PLGA NP, and popular because of 380 its ability to produce uniform NP with a size easily dispersed in aqueous media.
381
Importantly, residual PVA associated with PLGA NP can modify their bio-382 physicochemical properties (38) . The addition of PVA to the internal aqueous phase had 383 no impact on the residual PVA attached to all types of NP. Residual PVA determined in 384 different types of NP was less than 7%, being higher for PEGylated NP (Fig. 9) . The higher for its therapeutic activity (41) .
404
Aggregation is a major concern for protein-loaded PLGA microspheres, caused by hypoglycaemia. This is a foremost advantage for any insulin-containing formulation (20) .
442
Our results showed a clear effect on blood glucose concentration, which is in contrast to 443 the results of Liu et al. (37) , who showed insignificant decreases in blood glucose levels 444 following insulin-loaded NP administration within the first 12 hours.
445
Plasma insulin profiles closely mirrored blood glucose levels in all groups of mice,
446
confirming that the initial burst release and subsequent sustained release of insulin for the 447 
23
NP were key features of the improved glycaemic status (20) . Plasma insulin levels in mice 448 injected with free insulin (Fig. 12A) 
45
Legend to Figures   Fig. 1 . Sequence of steps comprising the double-emulsion, solvent evaporation technique. The factors investigated in this study were the insulin concentration, polymer type and PVA concentration in the primary emulsion. Fig. 2 . In vitro release profiles of NP prepared using PLGA (F1), 5%PEG-PLGA (F4) and 10%PEG-PLGA (F7) with insulin loading kept constant at 9% and no PVA in the secondary emulsion. Results are mean ± standard deviation (n=3). Results are mean ± standard deviation (n=3). ±SEM for 6 mice. **P < 0.01, ***P < 0.001 compared with free insulin.
